Previous article Next article

The EU Commission prohibits the acquisition of a genetic analysis provider by a cancer detection healthcare company (Grail / Illumina)

On 6 September 2022, the European Commission (the Commission ) prohibited the acquisition of cancer detection test start-up Grail by genetic and genomic analysis firm Illumina (see, attached Commission press releases). This decision formed the dramatic culmination of a procedure which the Commission had started on 19 April 2021 at the request of France, which was later joined by Belgium, Greece, The Netherlands and European Economic Area countries Iceland and Norway (see, Van Bael & Bellis Life Sciences News and Insights of 22 April 2021). The Commission considered to have that ability pursuant to Article 22 of the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Quotation

Michael Clancy, Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The EU Commission prohibits the acquisition of a genetic analysis provider by a cancer detection healthcare company (Grail / Illumina), 6 September 2022, e-Competitions Preview, Art. N° 108571

Visites 683

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues